Efficacy of an Infrared Visualization Technique for the Identification of the Peripheral Venous Access Site in Patients With Cystic Fibrosis Aged 12 Years and Older (MUCOVEINE)

July 6, 2022 updated by: Hospices Civils de Lyon

Cystic fibrosis is a rare chronic genetic disease that mainly affects the respiratory tract and the digestive system. Their management includes multi-year intravenous antibiotic treatments and repeated venous sampling. The venous access is a source of difficulties that nurses who take care of these patients face on a daily basis. In addition, multiple attempts at punctures can induce anxiety and pain in patients. It is therefore important to limit failures.

Vein visualization technologies exist: guidance echo, portable trans lumination or infrared visualization can guide venipuncture and limit failures.

Compared with the guided echo or the portable trans lumination, the infrared visualization is easy to use and does not pose a risk for the patient. Nevertheless, studies evaluating this technique are few in chronic diseases and mainly conducted in young children.

This study aims to show that the use of a vein illumination system (VIS) should improve the peripheral venous access at the first attempt (thus limiting venous lesions) in adolescent and adult patients with cystic fibrosis, and improve comfort of the patient (pain, apprehension of the gesture).

Study Overview

Status

Completed

Conditions

Detailed Description

Background :

Cystic fibrosis is a rare chronic genetic disease that mainly affects the respiratory tract and the digestive system. Their management includes multi-year intravenous antibiotic treatments and repeated venous sampling. The venous access is a source of difficulties that nurses who take care of these patients face on a daily basis. In addition, multiple attempts at punctures can induce anxiety and pain in patients. It is therefore important to limit failures.

Vein visualization technologies exist: guidance echo, portable trans lumination or infrared visualization can guide venipuncture and limit failures.

Compared with the guided echo or the portable trans lumination, the infrared visualization is easy to use and does not pose a risk for the patient. Nevertheless, studies evaluating this technique are few in chronic diseases and mainly conducted in young children.

This study aims to show that the use of a vein illumination system (VIS) should improve the peripheral venous access at the first attempt (thus limiting venous lesions) in adolescent and adult patients with cystic fibrosis, and improve comfort of the patient (pain, apprehension of the gesture).

Objectives of the study :

The main objective of the study is to demonstrate that the use of a vein illumination system (VIS) for the placement of a peripheral venous line or venous sampling on the hand, forearm or fold of the elbow improves peripheral venous access (PVA) successful on the first attempt.

The secondary objectives are :

  • To study the efficacy of VIS for peripheral venous access (placement of a peripheral venous line or peripheral venous sampling in the hand, forearm or elbow) on the number of attempts.
  • To study the impact of the use of SIV on the patient's pain felt during the peripheral venous access procedure.
  • To study the impact of VIS on patient anxiety prior to peripheral venous access.
  • To describe the nurses and nursing students satisfaction with the use of the VIS device for peripheral venous access.
  • To study the determinants of the success of peripheral venous access at the first attempt among the characteristics of nurses and nursing students (age, year of obtaining their diploma, experience within the cystic fibrosis ressource and competence center).
  • To describe the nurses and nursing students satisfaction with the use of A-DIVA scale.

Study design The study will last 36 months. It is an open and randomized multicenter cluster study, with sequential allocation of the device (stepped wedge allocation), comparing a group of patients benefiting from a technique of locating the puncture site by a venous illumination system for a peripheral venoux access (hand, forearm, fold of the elbow) to a group of patients whose veins are identified according to the usual modality of a peripheral venoux access. The cluster is defined by the Cystic Fibrosis Resource and Competence Center (CRCM).

Expected results

For the patients, the use of a venous illumination system device during the peripheral venous access should facilitate the success of the gesture on the first attempt, allowing to :

  • Reduce their pain due to multiple attempts.
  • Reduce their anxiety associated with peripheral venous access.
  • Preserve their venous capital This could have an impact on their care, such as making it easier to consult for them and being less anxious about peripheral venous access.

For the nurses, using a venous illimunation system device could

  • Reduce their apprehension of peripheral venous access gesture
  • Save their time with fewer peripheral venous access are repeated. It is considered that this technique will be distributed to all Cytic Fibrosis Ressource and Competence Centers (CRCM) in order to improving the comfort of the chronically ill patient with repeated blood tests and intravenous treatments.

Study Type

Interventional

Enrollment (Actual)

271

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Giens, France, 83406
        • CRCM mixte de Giens
      • Marseille, France, 13015
        • Hôpital Nord - CRCM adulte Marseille
      • Marseille, France, 13385
        • Hôpital enfant la Timone - CRCM pédiatrique Marseille
      • Montpellier, France, 34090
        • Hôpital Arnaud De Villeneuve
      • Nice, France, 06001
        • Hôpital Pasteur - CRCM adulte Nice
      • Nice, France, 06202
        • Hôpital Lenval - CRCM pédiatrique Nice

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with cystic fibrosis aged 12 years and over
  • Cystic Fibrosis diagnosis has been confirmed by a positive sweat test and/or 1 to 2 genetic mutations
  • Patients requiring peripheral venous access (hand, forearm, or more of the elbow) for intravenous infusion with epicranial or short catheter, or for a blood sample
  • Patients who have a score of 4 or higher on the A-DIVA scale (self-administered questionnaire completed by the IDE assessing the difficulty of peripheral venous access on a Likert scale from 0 to 8)
  • Patients informed in writing of the terms of the study and provided written informed consent to participate (consent of the person in charge of parental authority if the patient is a minor).
  • Patients affiliated to a social security system

Exclusion Criteria:

  • Patient who has already participated in the study
  • Patients who have a central venous approach
  • Patients who have a venous approach of the midline type
  • Patients taken care of for vital emergency
  • Patient deprived of liberty or placed under tutorship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Control Group
Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
EXPERIMENTAL: Experimental Group
Patients who have a peripheral venous access by a procedure using a Vein Illumination System.
Spotting veins of a patient by use of a Vein Illumintion System device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of patients for whom peripheral venous access was performed from the first attempt.
Time Frame: at time of peripheral venous access
at time of peripheral venous access

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of attempts to place a peripheral venous line or perform peripheral venous
Time Frame: at time of peripheral venous access
at time of peripheral venous access
Average pain score on Visual Analogue Scale (VAS) after successful peripheral venous access act.
Time Frame: at most 10 min after the venous act
at most 10 min after the venous act
Average anxiety score on State-Trait Anxiety Inventory (STAI-Y)
Time Frame: at most 10 min before the venous act
at most 10 min before the venous act
Proportion of nurses and nursing student satisfied by the use of a vein illumination system
Time Frame: at the end of the study ( at 14 months)
at the end of the study ( at 14 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 19, 2021

Primary Completion (ACTUAL)

May 12, 2022

Study Completion (ACTUAL)

May 12, 2022

Study Registration Dates

First Submitted

January 9, 2020

First Submitted That Met QC Criteria

January 10, 2020

First Posted (ACTUAL)

January 13, 2020

Study Record Updates

Last Update Posted (ACTUAL)

July 7, 2022

Last Update Submitted That Met QC Criteria

July 6, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cystic Fibrosis

Clinical Trials on Vein Illumintion System device

3
Subscribe